Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 11
Submit an article Journal homepage
75
Views
3
CrossRef citations to date
0
Altmetric
Review

The role of androgens in hormone replacement therapy

Crista E Johnson Female Sexual Medicine Center, Department of Urology, David Geffen School of Medicine at UCLA, 924 Westwood Blvd, Suite 515, Los Angeles, CA 90024, USA. [email protected]
&
Jennifer R Berman Female Urology and Female Sexual Medicine, Rodeo Drive Women’s Health Center, 421 North Rodeo Drive, Beverly Hills, CA 90210, USA
Pages 1815-1831 | Published online: 07 Sep 2005

Bibliography

  • LAUMANN EO, PAIK A, ROSEN RC: dysfunction in the United States, prevalence and predictors. JAMA (1999) 281(6):537–544.
  • •Analysis of the prevalence of FSD in the US.
  • MASTERS WH, JOHNSON VE: Human Sexual Response. Little Brown and Co., Boston, (1966).
  • KAPLAN HS: Disorders of sexual desire and other new concepts and techniques in sex therapy. Brunner/Mazel, Inc., New York, (1979).
  • ASSOCIATION AP: DSM-W and Statistical Manual of Mental. American Psychiatric Press, Washington, DC, (1994).
  • BASSON R, BERMAN J, BURNETT A et al.: Report of the International Consensus Development Conference on female sexual dysfunction: definitions and classifications. J. Urol (2000) 163:888–893.
  • •Guidelines for the classification of FSD.
  • BURGER HG: Androgen production in women. Fertil Steril (2002) 77\(Suppl. 4):53–55.
  • LABRIE C: Intracrinology. Mol. Cell. Endocrinol. (1991) 78:C113–C118.
  • BACHMANN G, BANCROFT J, BRAUNSTEIN G et al.: Female androgen insufficiency: the Princeton Consensus on definition, classification, and assessment. Fend Steril (2002) 77(4):660–665.
  • ••A key paper highlighting the PrincetonInternational Consensus Panel's guidelines for clinical assessment and diagnosis of female androgen insufficiency.
  • LONGCOPE C: Adrenal and gonadal androgen secretion in normal females. Clin. Endocrinol Metab. (1986) 15:213–227.
  • ENDOH A, KRISTIANSEN SB, CASSON RP, BUSTER JE, HORNSBY PJ: The Zona Reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex, resulting from its low expression of 3 beta hydroxysteroid dehydrogenase. J. Clin. Endocrinol Metab. (1991) 78:C113–118.
  • BABALOLA AA, ELLIS G: Serum dehydroepiandrosterone sulfate in a normal pediatric population. Clin. Biochem. (1985) 18:184–189.
  • ORENTREICH N, BRIND J, RIZER R, VOGELMAN J: Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. Clin. Endocrinol Metab. (1984) 59:551–555.
  • ZUMOFF B, ROSENFELD RS, STRAIN GW, FUKUSHIMA DK: Sex differences in the twenty-four hour mean plasma concentrations of dehydroepiandrosterone (DHA) and sulfate (DHAS) and the DHA:DHAS ratio in normal adults. J. Clin. Endocrinol Metab. (1980) 51:330–333.
  • ZUMOFF B, STRAIN GW, MILLER LK, ROSNER W: Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. Clin. Endocrinol Metab. (1995) 80:1429–1430.
  • MIGEON C, KELLER A. LAWRENCE B, SHEPART II T: Dehydroepiandrosterone and androsterone levels in human placenta. Effect of age and sex: day-to-day and diurnal variations. J. Clin. Endocrinol Metab. (1957) 17:1051–1062.
  • LABRIE F, BELANGER A, CUSAN L, GOMEZ JL, CANDAS B: Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging.. Endocrinol Metab. (1997) 82(8)2396–2402.
  • COLEMAN D, LEITER E, R: Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes (1982) 66:830–833.
  • BARRETT-CONNER E, KHAW K, YEN S: A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl. J. Med. (1986) 315:1519–1524.
  • NESTLER J, BARLASCINI C, CLORE J, BLACKARD W: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin in normal men. Clin. Endocrinol Metab. (1988) 66:57–61.
  • LONGCOPE C: Hormone dynamics at the. Ann. NY Acad. Sci. (1990) 592:21–30.
  • ABRAHAM GE: Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle.. Endocrinol Metab. (1974) 39:340.
  • LABRIE F, BELANGER A, SIMARD J: DHEA and peripheral androgen and estrogen formation: intracrinology. Ann IVY Acad Sci (1995) 774:16–28.
  • MORRIS NM, UDRY JR,-DAWOOD F, DAWOOD MY: Marital sex frequency and midcycle female testosterone. Arch. Sex. Behav. (1987) 16:27–37.
  • RILEY A, RILEY E: Controlled studies onwomen presenting with sexual drive disorder. I. Endocrine status.. Sex. Marital Ther. (2000) 26:269–283.
  • BURGER H, DUDLEY EC, CUT J, DENNERSTEIN L, HOOPER JL: A prospective longitudinal study of serum testosterone dehydroepiandrosterone sulphate and sex hormone binding globulin levels through the menopause transition. Clin. Endocrinol Metab. (2000) 85:2832–2938.
  • JUDD HL, LUCAS WE, YEN SCS: Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol Metab. (1974) 39:1020.
  • VERMUELEN A: Plasma androgens in women. J. Reprod. Med. (1998) 43\(Suppl. 8):725–733.
  • PERSKY H, DREISBACH L, WR et al.: The relation of plasma androgen levels to sexual behaviors and attitudes of women. Psychosom. Med. (1982) 44(4):305–319.
  • MCCOY NL, DAVIDSON JM: A longitudinal study of the effects of menopause on sexuality. Maturitas (1985) 7:203–210.
  • LOBO RA: Androgens in postmenopausal women: production, possible role, and replacement options. Obstet. GynecoL Surv. (2001) 56(6):361–376.
  • LASLEY BL, SANTORO N, JF et al.: The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the transition and ethnicity. J. Clin. Endocrinol Metab. (2002) 87:3760–3767.
  • •This article highlights ethnic variation in androgen levels throughout the meopause transition.
  • LONGCOPE C: Metabolic and blood production rates of estrogen in postmenopausal women. Am. J. Obstet. Gynecol (1971) 111:778–781.
  • VERMUELEN A: The hormonal activity of the postmenopausal ovary. J. Clin. Endocrinol Metab. (1976) 42:247–253.
  • ADASHI EY: The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fend. Steril. (1994) 62:20–27.
  • DOWSETT M, CANTWELL B, LAL A. JEFFCOATE SL, HARRIS AL: Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist Goserelin. j Clin. Endocrinol Metab. (1988) 66:672–677.
  • SLUIJMER AV HEINEMAN MJ, DE JONG FH, EVER JLH: Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J. Clin. Endocrinol Metab. (1995) 80:2163–2167.
  • COUZINET B, MEDURI G, LECCE MG et al.: The postmenopausal ovary is not a major androgen-producing gland. J. Clin. Endocrinol. Metab. (2001) 86:5060–5066.
  • ERICKSON GF, MAGOFFIN DA, DYER C, HOFEDITZ C: The ovarian androgen producing cells: a review of structure/function relationships. Endocr. Rev. (1985) 6:371–398.
  • HEINEMAN MJ, SLUIJMER AV EVER JLH: Utero-ovarian vein blood sampling in postmenopausal women. Fend. Steril. (1993) 60:184–186.
  • RINAUDO P, STRAUSS JF: Endocrine function of the postmenopausal ovary. Endocr. Metab. Clin. (2004) 33(4):661–674.
  • SIMON JA: Estrogen replacement therapy: effects on the endogenous androgen milieu. Fend. Steril. (2002) 77(4):577–582.
  • •A review of the scientific literature highlighting the impact of exogenous oestrogen replacement therapy on the production, binding and metabolism of ovarian and adrenal androgens.
  • LAUGHLIN GA,-CONNOR E, KRITZ-SILVERSTEIN D, MUHLEN D: Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J. Clin. Endocrinol Metab. (2000) 85(2):645–651.
  • LABRIE F, LUU V, LABRIE C et ell.: Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. (2003) 24:152–182.
  • UKKOLA O, RANKINEN T, J et al.: A genome-wide scan for steroids and SHBG levels in black and white females: the HERITAGE Family Study.. Endocrinol. Metab. (2002) 87:3708–3720.
  • FURUYAMA S: A radioimmunoassay forplasma testosterone. Steroids (1970) 16:415–428.
  • TAIEB J, MATHIAN B, MILLOT F et al.:Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women and children. Clin. Chem. (2003) 49(8):1381–1395.
  • KAPOOR P, LUTTZELL B, WILLIAMS D: The free androgen index is not valid for adult males. J. Steroid Biochem. Mol Biol. (1993) 45:325–326.
  • VERMEULEN A, VERDONCK L, KAUFMAN J: A critical evaluation of simple methods for the estimation of free testosterone in serum. Clin. Endocrinol. Metab. (1999) 84:3666–3672.
  • BUSTER JE: Hormonal aspects of HSDD. Contemp ob./gyn. (2004) (Suppl.):12–17.
  • PLOUFFE LJ: Ovaries, androgens and the menopause: practical applications.. Reprod. Endocrinol (1998) 16:117–120.
  • HUNT P, GURNELL E, HUPPERT F et al.: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's Disease in a randomized, double blind trial.. Endocrinol. Metab. (2000) 85:4650–4656.
  • LOVAS K, GEBRE-MEDHIN G, TROVIK T et al.: Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and in a 9 month, randomized, parallel group clinical trial.. Clin. EndocrinoL Metab. (2003) 88:1112–1118.
  • ARLT W, JUSTL H, CALLIES F et al.: dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J. Clin. EndocrinoL Metab. (1998) 83:1928–1934.
  • REIDEL M, WEISE A, T, BRABANT G: Quality of life in patients with's disease: effects of different cortisol replacement modes. Exp. Clin. EndocrinoL (1993) 101:106–111.
  • MILLER KK, BILLER BM, HIER J, ARENA E, KLIBANSKI A: Androgens and bone density in women with hypopituitarism. J. Clin. EndocrinoL Metab. (2002) 87:2770–2776.
  • ROSEN T, WILHELMSEN L,-WILHELMSEN K, LAPPAS G, BENGTSSON B: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. J. EndocrinoL (1997) 137:240–245.
  • ROSEN T, WIREN L, WILHELMSEN L, WIKLUND I, BENGTSSON B: Decreased psychological well-being in adult patients with growth hormone deficiency.. Clin. EndocrinoL Metab. (1994) 40:111–116.
  • JORGENSEN J, VAHL N, HANSEN T et al.: Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of boy composition. Clin. EndocrinoL (1996) 45:681–688.
  • VALIMAKI M, SALMELA P, SALMI J et al.: Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur. J. EndocrinoL (1999) 140:545–554.
  • MILLER KK, SESMILO G, SCHILLER A et al.: Androgen deficiency in women with hypopituitarism. j Clin. EndocrinoL Metab. (2001) 86:561–567.
  • ZELISSEN P, CROUGHS R, VAN RIJK P, RAYMAKERS J: Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. (1994) 120:207–210.
  • DEVOGELAER J, CRABBE J, NAGANT DE, DEUXCHAISNES C: Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br. Med. J. (1987) 294:798–800.
  • FLORKOWSKI C, HOLMES S, ELLIOT J, DONALD R, ESPINER E: Bone mineral density is reduced in female but not male subjects with Addison's disease. NZ Med. J. (1994) 107:52–53.
  • FINDLING J, BUGGY B, GILSON I, ALE: Longitudinal evaluation of adrenocortical function in patients infected with the human immunodeficiency virus. Clin. EndocrinoL Metab. (1994) 79:1091–1096.
  • LAAN E, VAN LUNSEN RH: Hormones and sexuality in postmenopausal women: a psychophysiological study.. Obstet. GynaecoL (1997) 18:126–133.
  • SARREL PM: Sexuality and menopause. Obstet. GynecoL (1990) 75(Suppl.):526–30.
  • SARREL PM: Ovarian hormones and vaginal blood flow using laser doppler velocimetry to measure effects in a clinical trial in postmenopausal women.. J. Impot. Res. (1998) 10:S91–S93.
  • TRAISH AM, KIM N, MIN K, MUNARRIZ R, GOLDSTEIN I: Role of Androgens in female genital sexual arousal: receptor expression, structure and function. FertiL SteriL (2002) 77(4):S11–518.
  • SIMON JA, KLAIBER E, WIITA B, BOWEN A, YANG HM: Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause (1999) 6:138–146.
  • SARREL PM: Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. Health Gend. Based Med. (2000) 9\(Suppl. 1):525–532.
  • STENBERG A, HEIMER G, ULMSTEN U: The prevalence of urogenital symptoms in post-menopausal women. Maturitas (1995) 22(Suppl.):517–520.
  • SIMPSON ER: Aromatization of androgens in women: current concepts and findings. FertiL SteriL (2002) 77\(Suppl. 4):56–S10.
  • BULUN SE, SIMPSON ER: Competitive reverse transcription-polymerase chain analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs and abdomen of women increase with advancing age. J. Clin. Endocrinol. Metab. (1994) 78:428–432.
  • LONGCOPE C, BALER S: Androgen and estrogen dynamics: relationships with age, weight and menopause status.. EndocrinoL Metab. (1993) 76:601–604.
  • CASSON PR, ELKIND-HIRSCH KE, BUSTER JE et al.: Effect of postmenopausal estrogen replacement on circulating androgens. Obstet. GynecoL (1997) 90:995–998.
  • TAZUKE S, SHAW KT: Exogenous estrogen and endogenous sex hormones. Medicine (1992) 71:44–51.
  • JUDD HL: Hormonal dynamics associated with the menopause. Clin. Obstet. GynecoL (1976) 19:775–788.
  • GEIST SH, SALMON UJ: Androgen therapy in gynecology. JAMA (1941) 117:2207–2213.
  • GREENBLATT RB, BARFIELD WE, GARNER JF et al.: Evaluation of an estrogen, androgen, and estrogen-androgen combination, and a placebo in the treatment of the menopause. Clin. Endocrinol Metab. (1950) 10:1547–1558.
  • GELFAND MM, FERENZY A. BERGERON C: Menopause: Evaluation, treatment, and health concerns. AR Liss (Ed.), Inc, New York, (1989):29–40.
  • SIMON JA, NACHTIGAL LE, DAVIS SRet al.: Transdermal testosterone patch improves sexual activity and desire in surgically menopausal women. Obstet. GynecoL (2004) 103\(Suppl. 4):645.
  • STANCZYK F, SHOUPE D, NUNEZ V et al.: A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am. J. Obstet. GynecoL (1988) 159:1540–1546.
  • JAVANBAKHT M, SINGH A, MAZER N et al.: Pharmacokinetics of a novel testosterone matrix transdermal system in health, premenopausal women and women infected with the human immunodeficiency virus. J. Clin. EndocrinoL Metab. (2000) 85:2395–2401.
  • SHIFREN JL, BRAUNSTEIN GD, SIMON JA et al.: Transdermal testosterone treatment in women with impaired sexual after oophorectomy. Engl. J. Med. (2000) 343:682–688.
  • •A key paper on the effects of transdermal testosterone on sexual function in surgically menopausal women.
  • SHERWIN BB: Randomized clinical trials combined estrogen-androgen preparations: effects on sexual functioning. Fend Steril. (2002) 77(4):549–554.
  • •A review of randomised controlled trials of the efficacy of combined oestrogen-androgen preparations on sexual functioning in postmenopausal women.
  • GOLDSTAT R, BRIGANTI E, TRAN J, WOLFE R, DAVIS SR: Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. (2003) 10(5):390–398.
  • •A key paper on the effects of transdermal testosterone on sexual function in premenopausal women.
  • DOW MGT, HART DM, FORREST CA: Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study.. J. Obstet. Gynaecol (1983) 90:361–366.
  • MYERS LS, DIXEN J, M, CARMICHAEL M, DAVIDSON JM: Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women.. Endocrinol Metab. (1990) 70(4):1124–1131.
  • BURGER HG, HAILES J, M et al.: The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas (1984) 6:351–358.
  • DAVIS SR, MCCLOUD P, STRAUSS BJ, BURGER H: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas (1995) 21:227–236.
  • BURGER H, HAILES J, NELSON J, MENELAUS M: Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br. Med. J. (1987) 294:936–937.
  • SHERWIN BB, GELFAND MM, BRENDER W: Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom. Med. (1985) 47(4):339–351.
  • SHERWIN BB, GELFAND MM: The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom. Med. (1987) 49:397–409.
  • SARREL P, DOBAY B, WIITA B: Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy sexual behavior and neuroendocrine responses. J. Reprod. Med. (1998) 43(10):847–856.
  • LOBO RA, ROSEN RC, YANG HM, BLOCK B, GERRITSEN VAN DER HOOP R: Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fend Steril (2003) 79(6):1341–1352.
  • KLOOSTERBOER H: Intracrinology: the secret of the tissue-specificity of tibolone. J. Br. Menopause Soc. (2000) 6(Suppl.):23–27.
  • TAX L, GOORISSEN E, KICOVIC P: Clinical profile of Org OD 14. Maturitas (1987) 1(Suppl.):3–13.
  • DOREN M, RUBIG A, COELINGH BENNINK H, HOLZGREVE W: Differential effects of the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril (2001) 75:554–559.
  • LAAN E, VAN LUNSEN RH, W: The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric (2001) 4:28–41.
  • NATHORST-BOOS J, HAMMAR M: Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas (1997) 26:15–20.
  • PARASRAMPURIA J, SCHWARTZ K, PETESCH MR: Quality control of dehydroepiandrosterone dietary supplement products. JAMA (1998) 280(19):1565.
  • VILLAREAL DT, HOLLOSZY JO, KOHRT WM: Effects of DHEA replacement on bone mineral density and body composition in elderly men and women. Clin. Endocrinol (2000) 3:561–568.
  • DERKSEN RHWM: and systemic lupus erythematosus.. Arthritis Rheum. (1998) 27:335–347.
  • KATZ S, MORALES AJ: (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause. Semin. Reprod. Endocrinol (1998) 16:161–170.
  • SPARK RF: Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil Steril (2002) 77\(Suppl. 4):519–525.
  • BARRETT-CONNOR E, FERRARA A: Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study.. Endocrinol. Metab. (1996) 81:59–64.
  • BARRETT-CONNOR E, GOODMAN-GRUEN D: Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation (1995) 91:1757–1760.
  • GORDON GB, T.L.; B, KJ, MILLER SR, COMSTOCK GW: Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res. (1990) 50:3859–3862.
  • YOUNG J, COUZINET B, NAHOUL K et al.: Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. J. Clin. Endocrinol. Metab. (1997) 82:2578–2585.
  • ARLT W, CALLIES F, VAN VLIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl J. Med. (1999) 341(14):1013–1020.
  • CALLIES F, FASSNACHT M, CHRISTOPH VAN VLIJMEN J et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J. Clin. Endocrinol Metab. (2001) 86:1968–1972.
  • MORTOLA J, YEN S: The effect of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J. Clin. Endocrinol Metab. (1990) 71:696–704.
  • WELLE S, JOZEFOWICZ R, STATT M: Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J. Clin. Endocrinol Metab. (1990) 71:1259–1264.
  • RAVNIKAR VA: Use of DHEA in menopause practice. Menopausal Med. (2004) 12(2):10–12.
  • BARRY NN, MCGUIRE JL, VOLLENHOVEN RF: in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.. RheumatoL (1998) 25:2352–2356.
  • MORALES AJ, NOLAN JJ, NELSON YC: Effects of a replacement dose of dehydroepiandrosterone in men and women of advanced age.. Clin. EndocrinoL Metab. (1994) 78:1360–1367.
  • FLYNN MA,-OSTERHOLTZ D, SHARPE-TIMMS KL, ALLEN S, KRAUSE G: Dehydroepiandrosterone replacement in aging humans. J. Clin. EndocrinoL Metab. (1999) 84:1527–1533.
  • JOHANNSSON G, BURMAN P, WIREN L et ell.: Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. EndocrinoL Metab. (2002) 87:2046–2052.
  • BASARIA S, DOBS k Safety and adverse effects of androgens: how to counsel patients. Mayo Clin. Proc. (2004) 79(Suppl.):525–532.
  • •A comprehensive review of the and adverse effects of androgen replacement therapy.
  • MOORE E, WISNIEWSKI A, DOBS A: Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.. Clin. EndocrinoL Metab. (2003) 88:3467–3473.
  • SHERWIN BB, GELFAND MM: Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. PsychoneuroendocrinoL (1985) 10:325–335.
  • WATTS N, NOTELOVITZ M, TIMMONS M et al.: Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet. GynecoL (1995) 85:529-537, erratum 85:668.
  • HICKOK L, TOOMEY C, SPEROFF L: A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum in postmenopausal women. Obstet. GynecoL (1993) 82:919–924.
  • BUCKLER H, MCELHONE K, DURRINGTON P et al.: The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin. EndocrinoL (1998) 49:173–178.
  • BASARIA S, NGUYEN T, R, DOBS A: Effect of methyltestosterone administration on plasma viscosity in postmenopausal women. Clin. EndocrinoL (2002) 57:209–214.
  • URMAN B, PRIDE S, YUEN B: Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet. GynecoL (1991) 77:595–598.
  • BASARIA S, WAHLSTROM J, DOBS A: Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases./ Clin. EndocrinoL Metab. (2001) 86:5108–5117.
  • DAVIS SR, HUMBERSTONE A. MILNE RW, EVANS AM: Measurement of serum total testosterone levels after administration of testosterone can underestimate the amount of testosterone that has been absorbed. The Endocrine Society 85th Annual Meeting., PA (2003).
  • DAVIS S: Androgen replacement in women: a commentary. Clin. EndocrinoL Metab. (1999) 84:1886–1891.
  • BRAUNSTEIN GD: Androgen in women: summary of critical issues. FertiL SteriL (2002) 77\(Suppl. 4):594–599.
  • •This is a summary of key issues concerning the role of androgens in the physical, sexual and emotional health of women.
  • DIMITRAKAKIS C, ZHOU J, CA: Androgens and mammary growth and neoplasia. FertiL Steril. (2002) 77\(Suppl. 4):526–533.
  • •An evaluation of the effects of androgens on breast cancer development.
  • RECCHIONE C, VENTURELLI E, MANZARI A et al.: Testosterone, dihydrotestosterone, and oestradiol levels in postmenopausal breast cancer tissues. J. Steroid Biochem. MoL Biol. (1995) 52:541–546.
  • BRYAN RM, MERCER RJ, RENNIE GC, LIE TH, MORGAN FJ: Androgen in breast cancer. Cancer (1984) 54:2436–2440.
  • LI S, YAN X, BELANGER A, LABRIE F: Prevention by dehydroepiandrosterone of the development of mammary induced by 7, 12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res. Treat. (1993) 29:203–217.
  • LABRIE C, BELANGER A, LABRIE F: Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology (1988) 123:1412–1417.
  • LABRIE C, SIMARD J, ZHAO H et aL: Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology (1989) 124:2745–2754.
  • BULBROOK R, HAYWARD J, SPICER C: Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet (1971) 2:395–398.
  • WANG D, BULBROOK R, HAYWARD J: Urinary and plasma androgens and their relation to familial risk of breast cancer. Eur. J. Cancer (1975) 11:873–877.
  • ZUMOFF B, LEVIN J, ROSENFELD R et al.: Abnormal 24-hr mean plasma concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfate in women with primary operable breast cancer. Cancer Res. (1981) 41:3360–3363.
  • SEGALOFF k HAYWARD B, CARTER A, BUNDY B, MASNYK I: Identification of breast cancer patients with high risk of early recurrence after radical mastectomy: III. Steroid hormones measured in urine. Cancer (1980) 46:1087–1092.
  • LIU P, DEATH k HANDELSMAN D: Androgens and cardiovascular disease. Endocr. Rev. (2003) 24(3):313–340.
  • KANNEL W, HJORTLAND M, MCNAMARA P, GORDON T: Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. (1976) 85:447–452.
  • BASARIA S, DOBS A: Treatment of hyperlipidemia in women. Int. J. Fend Womens Med. (2000) 45:22–33.
  • GOTTO A: Triglyceride as a risk factor for coronary artery disease. Am. J. Cardiol. (1998) 82(9A):22Q–25Q.
  • WORBOYS S, KOTSOPOULOS D, TEEDE H, MCGRATH B, DAVIS S: Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J. Clin. Endocrinol. Metab. (2001) 86:158–161.

Websites

  • http://www.fda.gov/cder/guidance/ 3312dft.htm for industry female sexual dysfunction: clinical development of drug products for treatment. Center for Drug Evaluation and Research (CDER). US Dept Health Human Services, Rockville, MD (2000).
  • •This draft document by the CDER of the US FDA outlines recommendations on the design of clinical trials evaluating drug treatment paradigms for FSD.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.